LAEKNA-B (02105): Enrollment Completed for Phase III Clinical Trial (AFFIRM-205) of LAE002 (Afuresertib) in HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Stock News12-15

LAEKNA-B (02105) announced that the group has completed patient enrollment for the Phase III clinical trial AFFIRM-205, evaluating LAE002 (afuresertib) in combination with fulvestrant for the treatment of HR+/HER2- locally advanced or metastatic breast cancer (LA/mBC) in patients with PIK3CA/AKT1/PTEN genetic alterations.

AFFIRM-205 is a multicenter, randomized, double-blind, placebo-controlled pivotal study designed to assess the antitumor efficacy and safety of the combination therapy. The group aims to release topline data from this Phase III pivotal study in the first half of 2026 and submit a new drug application to China's National Medical Products Administration later that year.

On November 12, 2025, the group entered into an exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. Under the terms of the agreement, Qilu Pharmaceutical obtained exclusive rights to research, develop, and commercialize LAE002 (afuresertib) in China, including the mainland, Hong Kong SAR, Macau SAR, and Taiwan region.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132712108?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 08:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132712108","market":"hk","top_or_hot":-1,"title":"LAEKNA-B (02105): Enrollment Completed for Phase III Clinical Trial (AFFIRM-205) of LAE002 (Afuresertib) in HR+/HER2- Locally Advanced or Metastatic Breast Cancer","media":"Stock News","content":"<p>LAEKNA-B (02105) announced that the group has completed patient enrollment for the Phase III clinical trial AFFIRM-205, evaluating LAE002 (afuresertib) in combination with fulvestrant for the treatment of HR+/HER2- locally advanced or metastatic breast cancer (LA/mBC) in patients with PIK3CA/AKT1/PTEN genetic alterations.</p>\n<p>AFFIRM-205 is a multicenter, randomized, double-blind, placebo-controlled pivotal study designed to assess the antitumor efficacy and safety of the combination therapy. The group aims to release topline data from this Phase III pivotal study in the first half of 2026 and submit a new drug application to China's National Medical Products Administration later that year.</p>\n<p>On November 12, 2025, the group entered into an exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. Under the terms of the agreement, Qilu Pharmaceutical obtained exclusive rights to research, develop, and commercialize LAE002 (afuresertib) in China, including the mainland, Hong Kong SAR, Macau SAR, and Taiwan region.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LAEKNA-B (02105): Enrollment Completed for Phase III Clinical Trial (AFFIRM-205) of LAE002 (Afuresertib) in HR+/HER2- Locally Advanced or Metastatic Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLAEKNA-B (02105): Enrollment Completed for Phase III Clinical Trial (AFFIRM-205) of LAE002 (Afuresertib) in HR+/HER2- Locally Advanced or Metastatic Breast Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-15 08:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LAEKNA-B (02105) announced that the group has completed patient enrollment for the Phase III clinical trial AFFIRM-205, evaluating LAE002 (afuresertib) in combination with fulvestrant for the treatment of HR+/HER2- locally advanced or metastatic breast cancer (LA/mBC) in patients with PIK3CA/AKT1/PTEN genetic alterations.</p>\n<p>AFFIRM-205 is a multicenter, randomized, double-blind, placebo-controlled pivotal study designed to assess the antitumor efficacy and safety of the combination therapy. The group aims to release topline data from this Phase III pivotal study in the first half of 2026 and submit a new drug application to China's National Medical Products Administration later that year.</p>\n<p>On November 12, 2025, the group entered into an exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. Under the terms of the agreement, Qilu Pharmaceutical obtained exclusive rights to research, develop, and commercialize LAE002 (afuresertib) in China, including the mainland, Hong Kong SAR, Macau SAR, and Taiwan region.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"III","symbol_name":"信息服务","start_time":0,"source_url":"","article_id":"1132712108","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132712108","pubTimestamp":1765758016,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LAEKNA-B (02105) announced that the group has completed patient enrollment for the Phase III clinical trial AFFIRM-205, evaluating LAE002 (afuresertib) in combination with fulvestrant for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"III":"信息服务","BK4134":"信息科技咨询与其它服务","02105":"来凯医药-B","BK4225":"医疗保健房地产信托","BK1161":"生物科技","HR":"医疗保健房地产信托","BK4203":"医疗保健房地产投资信托"},"translate_title":"LAEKNA-B（02105）：LAE002（Afuresertib）治疗HR+/HER2-局部晚期或转移性乳腺癌的III期临床试验（AFFIRM-205）已完成入组","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1,"HR":1,"02105":1},"content_text":"LAEKNA-B (02105) announced that the group has completed patient enrollment for the Phase III clinical trial AFFIRM-205, evaluating LAE002 (afuresertib) in combination with fulvestrant for the treatment of HR+/HER2- locally advanced or metastatic breast cancer (LA/mBC) in patients with PIK3CA/AKT1/PTEN genetic alterations.\nAFFIRM-205 is a multicenter, randomized, double-blind, placebo-controlled pivotal study designed to assess the antitumor efficacy and safety of the combination therapy. The group aims to release topline data from this Phase III pivotal study in the first half of 2026 and submit a new drug application to China's National Medical Products Administration later that year.\nOn November 12, 2025, the group entered into an exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. Under the terms of the agreement, Qilu Pharmaceutical obtained exclusive rights to research, develop, and commercialize LAE002 (afuresertib) in China, including the mainland, Hong Kong SAR, Macau SAR, and Taiwan region.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132712108","isCrawlerRequest":true}